Apixaban versus antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation. A randomised phase II clinical trial.

Trial Profile

Apixaban versus antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation. A randomised phase II clinical trial.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs Apixaban (Primary) ; Antiplatelets
  • Indications Stroke; Thromboembolism
  • Focus Therapeutic Use
  • Acronyms APACHE-AF
  • Most Recent Events

    • 17 Jan 2015 Status changed from not yet recruiting to recruiting, as reported by Netherlands Trial Register record.
    • 01 Jan 2015 Trial design presented.
    • 04 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top